Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -59.00 -2.66% 2,156.00 387,699 16:35:20
Bid Price Offer Price High Price Low Price Open Price
2,153.00 2,155.00 2,219.00 2,154.00 2,214.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,661.14 370.23 151.41 14.1 5,243
Last Trade Time Trade Type Trade Size Trade Price Currency
18:33:05 O 19 2,160.034 GBX

Hikma Pharmaceuticals (HIK) Latest News

More Hikma Pharmaceuticals News
Hikma Pharmaceuticals Takeover Rumours

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
29/7/202009:44Hikma Pharmaceuticals1,030
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-04 17:33:062,160.0319410.41O
2020-08-04 17:31:212,157.438172.59O
2020-08-04 17:31:192,164.5541887.46O
2020-08-04 17:28:472,156.0028603.68O
2020-08-04 17:28:402,163.501,92641,668.93O
View all Hikma Pharmaceuticals trades in real-time

Hikma Pharmaceuticals (HIK) Top Chat Posts

Hikma Pharmaceuticals Daily Update: Hikma Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 2,215p.
Hikma Pharmaceuticals Plc has a 4 week average price of 2,087p and a 12 week average price of 2,087p.
The 1 year high share price is 2,670p while the 1 year low share price is currently 1,596p.
There are currently 243,169,353 shares in issue and the average daily traded volume is 461,842 shares. The market capitalisation of Hikma Pharmaceuticals Plc is £5,242,731,250.68.
r ball: Share price movement triggered by genetics news? Has there been a clamp down on Indian competitors?
broadwood: Share price reaction could have been worse. No point in selling at the bottom, if indeed it should prove so.
r ball: If fda settlement was sorted I would expect share price of £25. The main issue is Indian access to us generics market.
justiceforthemany: MULDER on LSE ANALYSIS OF HIKMA FUNDAMENTALS 52 week range: 1330-2324 43% off the 52 week high - pretty much all due to the delayed Generic Advair ruling - one inhaler! Was trading around 2300 as recently as March 15th 2017 Market Cap £3.2Bn Description of business Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma’s operations are in the United States, the Middle East and North Africa Region and Europe. Debt:Equity ratio = 0.53 This is better than GSK, AZN, Shire Equity ratio (current) 2.24 Equity ratio excluding all intangibles and 'goodwill' = 1.35 These figures are very good and far better than the larger drug companies like GSK, AZN and Shire. Hikma has a solid balance sheet. Book value/NAV = 1000p P:B ratio 1.3x This is again better than GSK and AZN whilst on a par with Shire. Revenue has doubled in the past 5 years from £1.1Bn to £2Bn currently Profits were distorted last year due to exceptionals but even taking this into account operating profit has averaged £360M/year. Projected revenue for this year ~ £2Bn EPS projected ~ 90p P/E 2017 ~ 14.8 EPS 2018 projected 102p P/E 2018 ~ 13 Historic P/E is around 21x so huge discount to this currently and compared to wider pharmaceutical sector. Dividend yield low around 1.8% but excellent cover at 3.6x so great scope for increases Shorts have also decreased in recent days which makes the drop even more suspect. All in all solid balance sheet, trading at 4 year share price lows, defensive sector, chance of take-over, global and diverse company, low P/E, great dividend cover, low PEG 2018/earnings to grow 2018 onwards. This makes the near 50% fall in share price over just 5 months and the shorters' interest here all the more baffling. What do you guys think?
fez77: Interactive Investor:- Still, analysts remain undeterred. Stifel's Max Herrmann reckons the stock can recapture August highs at the £23 level, with his unchanged target price now suggesting potential upside of 43%. This despite "ongoing difficulties" in delivering the potential of its February 2016 acquisition of Roxane Laboratories. Herrmann reckons the lowering of its Generics forecasts will slash 4% off Hikma's earnings per share. However, he remains "confident of Hikma's long-term potential, with generic Advair, first to file Zytiga and first to file Xyrem opportunities still to come". A forecast 2017 price/earnings (PE) ratio of 19.6 times represents an 18% discount to its UK specialty peers and means the firm's potential is not currently reflected in the share price, Herrmann added.
bantam175: This is nuts. They've dropped their revenue forecast by $130million which has brought the share price down from £22 to here £16.5 Reducing the company value by 239970000 (shares in issue)* 5.5 (£'s drop in price) = £1,319,835,000. They must be a bargain at this price surely? Drop over last couple of months seems completely out of all proportion to me. imho dyor etc.
vatattack: Hikma Pharmaceuticals got a boost on Monday as Numis upgraded the stock to 'buy' from 'add'.It said that following Mylan's Complete Response Letter, the market is now overly discounting Hikma's prospects for gaining approval of its generic version of GlaxoSmithKline's bestselling asthma drug Advair this year.In addition, the share price is now also heavily discounting the core business, Numis said."If Hikma gains FDA approval this year, most likely with minor deficiencies in a complete response letter, we see potential for a slight upgrade to our low-end FY17 forecasts, and a material upgrade to our low-end FY18 forecasts (potentially more than 10%), and envisage a higher multiple being warranted post upgrades (14x FY18 EV/EBITDA well underpinned versus peers)."Numis reckons Hikma has a stronger chance of approval than Mylan because it included 12-18 year olds in its study and has benefited from the expertise of Vectura, a business that, unlike Mylan, has a generic version of Advair Diskus approved in Europe in partnership with Sandoz."In our opinion the current share price is well underpinned by the core business (more than 25% upside), with a free option on generic Advair. This is an asymmetric risk worth taking, with the catalyst now a month away and potential for more than 50% returns if Hikma's generic Advair is approved first time, or with minor deficiencies."In its final results on 15 March, Hikma said it expected revenue for the Generics business to be around $800m this year, with an improvement in the mix of sales and new product launches more than offsetting the impact of increased competition on the marketed portfolio and a reduction in contract manufacturing revenue.The group said certain new launches were expected to contribute around 15% of Generics revenue in 2017, primarily generic Advair, which was assumed to be launched in the second half of the year.Numis has a 2,350p price target on Hikma.
broadwood: Hikma Pharmaceuticals Plc using EPIC/TICKER code LON:HIK has had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Cantor Fitzgerald. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Cantor Fitzgerald have set a target price of 2500 GBX on its stock. This now indicates the analyst believes there is a possible upside of 14.7% from the opening price of 2180 GBX. Over the last 30 and 90 trading days the company share price has increased 205 points and increased 450 points respectively
fez77: No idea when next trading statement will be but full years figures should be available in March. Darhold appears to be a vehicle for Directors etc to hold shares in Hikma. An old Guardian article (May 2015)at included the quote:- "The Jordanian-based company has expanded rapidly over the past few years by building a world-class injectable generics business and enjoyed strong growth as a branded pharma player in its home MENA markets. Following the recent decline in Hikma’s share price, the company now trades at a 10% 2015 PER discount to its peers. We believe the sell-off is overdone, and we are therefore upgrading our recommendation to Buy. Any reticence to consider Hikma seems to primarily be concerned with Hikma’s roots as a Jordanian, family-run company with a large operation in the Middle East. However, with the family controlling 28.8% of the company through their Darhold Ltd stake, management interests are well aligned with the shareholders. We believe large acquisitions are possible in the near future and will remain an integral part of Hikma’s business plan...." As I said before, it is a bumpy ride, but one where the largest shareholders are prepared to put their money where their mouth is!
broadwood: Numis has upgraded its recommendation on Hikma Pharmaceuticals [LON:HIK] to 'buy' from 'hold' ahead next week's third quarter update and following a 35 per cent decline in the share price over the past three months. The broker pointed out that the shares have significantly underperformed the UK Mid-Cap Healthcare and Global Specialty Pharma sectors but sees the Q3 results on 10th November and the "Meet the Management" event on 15th November as the catalysts for a re-rating. Analyst have set a new target price of 2,350 pence per share
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200805 02:34:53